For depression and/or anxiety. ANDA 210675, held by Epic Pharma LLC. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 210675 (Doxepin Hydrochloride), held by Epic Pharma LLC, was first approved by FDA on Oct 16, 2020, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Doxepin hydrochloride capsule is recommended for the treatment of: 1. Psychoneurotic patients with depression and/or anxiety. 2. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). 3. Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). 4. Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 16, 2020 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 10MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 25MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 100MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 50MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 75MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Aug 27, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 27, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 21, 2020 | Supplement 1 | Approved | None posted |
| Oct 16, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters